On an episode of the Joe Rogan Experience (#2537), Harvard longevity researcher David Sinclair made a striking claim about GLP-1 receptor agonist treatments, linking them to a dramatic rise in cases of sudden blindness. Sinclair raised the issue while discussing his lab’s gene therapy work on vision-related diseases, noting that one of the conditions his research targets is NAION, nonarteritic anterior ischemic optic neuropathy.
“It’s calle…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.